Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNFW 180 Life Sciences	$0.11 +834.2%	$0.01	$0.00 ▼ $0.15	N/A	N/A	309,822 shs	25.72 million shs
SOLTF Nxera Pharma	$6.50 +4.5%	$6.43	$5.50 ▼ $10.62	N/A	N/A	731 shs	100 shs
SXTPW 60 Degrees Pharmaceuticals	$0.15 +34.1%	$0.06	$0.01 ▼ $0.16	N/A	N/A	14,934 shs	17,508 shs
TRSBF 3SBio	$4.00 -4.8%	$3.44	$2.22 ▼ $4.74	N/A	N/A	1,792 shs	500 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNFW 180 Life Sciences	-6.56%	+7.55%	+40.74%	+22.58%	+7.55%
SOLTF Nxera Pharma	+4.50%	+4.84%	+4.84%	+9.98%	-35.96%
SXTPW 60 Degrees Pharmaceuticals	+0.27%	+122.91%	+97.35%	+87.75%	+86.50%
TRSBF 3SBio	0.00%	+1.39%	+25.00%	+383.15%	+421.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNFW 180 Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SOLTF Nxera Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRSBF 3SBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNFW 180 Life Sciences	N/A	N/A	N/A
SOLTF Nxera Pharma	N/A	N/A	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A
TRSBF 3SBio	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNFW 180 Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A
SOLTF Nxera Pharma	N/A	N/A	N/A	N/A	N/A	N/A
SXTPW 60 Degrees Pharmaceuticals	$665.45K	N/A	N/A	N/A	N/A	N/A
TRSBF 3SBio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNFW 180 Life Sciences	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
SOLTF Nxera Pharma	N/A	N/A	∞	N/A	N/A	N/A	N/A	10/31/2025 (Estimated)
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
TRSBF 3SBio	N/A	N/A	∞	N/A	N/A	N/A	N/A	8/20/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNFW 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
SOLTF Nxera Pharma	N/A	N/A	N/A	N/A	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRSBF 3SBio	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNFW 180 Life Sciences	N/A
SOLTF Nxera Pharma	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A
TRSBF 3SBio	N/A

Insider Ownership

Company	Insider Ownership
ATNFW 180 Life Sciences	N/A
SOLTF Nxera Pharma	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A
TRSBF 3SBio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNFW 180 Life Sciences	7	N/A	N/A	Not Optionable
SOLTF Nxera Pharma	360	N/A	N/A	Not Optionable
SXTPW 60 Degrees Pharmaceuticals	2	N/A	N/A	Not Optionable
TRSBF 3SBio	5,411	N/A	N/A	Not Optionable

SOLTF, ATNFW, TRSBF, and SXTPW Headlines

Recent News About These Companies

Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update

May 20, 2025 | marketwatch.com

Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer

May 20, 2025 | marketwatch.com

Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion

May 20, 2025 | msn.com

Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China

July 28, 2022 | markets.businessinsider.com

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

August 26, 2021 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLTF, ATNFW, TRSBF, and SXTPW Company Descriptions

180 Life Sciences NASDAQ:ATNFW

$0.11 +0.10 (+834.21%)

As of 03:59 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Nxera Pharma OTCMKTS:SOLTF

$6.50 +0.28 (+4.50%)

As of 08/11/2025 09:35 AM Eastern

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily; and strategic research and development partnership with PrecisionLife to auto-immune disorders with the potential to identify new drug targets for the treatment of chronic conditions. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.15 +0.04 (+34.14%)

As of 03:17 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

3SBio OTCMKTS:TRSBF

$4.00 -0.20 (-4.76%)

As of 08/11/2025 02:23 PM Eastern

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time